TW202400146A - 美羅培南與法硼巴坦的組合之用途 - Google Patents

美羅培南與法硼巴坦的組合之用途 Download PDF

Info

Publication number
TW202400146A
TW202400146A TW112133851A TW112133851A TW202400146A TW 202400146 A TW202400146 A TW 202400146A TW 112133851 A TW112133851 A TW 112133851A TW 112133851 A TW112133851 A TW 112133851A TW 202400146 A TW202400146 A TW 202400146A
Authority
TW
Taiwan
Prior art keywords
subject
meropenem
item
patent application
administered
Prior art date
Application number
TW112133851A
Other languages
English (en)
Chinese (zh)
Inventor
伊麗莎白 亞利山大
傑夫 盧蒂
麥可Ｎ 達德利
Original Assignee
美商萊姆派克斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202400146(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商萊姆派克斯製藥公司 filed Critical 美商萊姆派克斯製藥公司
Publication of TW202400146A publication Critical patent/TW202400146A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112133851A 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途 TW202400146A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US62/567,702 2017-10-03
US201862657402P 2018-04-13 2018-04-13
US62/657,402 2018-04-13

Publications (1)

Publication Number Publication Date
TW202400146A true TW202400146A (zh) 2024-01-01

Family

ID=65994826

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112133851A TW202400146A (zh) 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途
TW107134824A TW201922241A (zh) 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107134824A TW201922241A (zh) 2017-10-03 2018-10-02 美羅培南與法硼巴坦的組合之用途

Country Status (16)

Country Link
US (3) US11376237B2 (https=)
EP (1) EP3691652A4 (https=)
JP (1) JP2020536092A (https=)
KR (1) KR20200066664A (https=)
CN (1) CN111432821A (https=)
AU (1) AU2018345317B2 (https=)
BR (1) BR112020006658A2 (https=)
CA (1) CA3078238A1 (https=)
CL (1) CL2020000892A1 (https=)
JO (1) JOP20200075A1 (https=)
MX (1) MX2020003670A (https=)
MY (1) MY200934A (https=)
PH (1) PH12020550249A1 (https=)
SG (1) SG11202003009QA (https=)
TW (2) TW202400146A (https=)
WO (1) WO2019070591A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020006658A2 (pt) * 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas
TW202304469A (zh) * 2021-03-24 2023-02-01 美商杜夫特學院信託管理公司 酸化合物、組合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
US9993469B2 (en) 2013-05-28 2018-06-12 Morphochem Aktiengesellschaft Für Kombinatorishe Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
ES2942329T3 (es) * 2015-04-24 2023-05-31 Melinta Therapeutics Inc Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida
JP6845511B2 (ja) 2015-07-09 2021-03-17 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 抗細菌性薬剤併用物の組成物及び使用方法
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
MX390529B (es) 2017-01-09 2025-03-20 Rempex Pharmaceuticals Inc Metodos para tratar infecciones bacterianas
BR112020006658A2 (pt) 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas

Also Published As

Publication number Publication date
CA3078238A1 (en) 2019-04-11
US11376237B2 (en) 2022-07-05
EP3691652A1 (en) 2020-08-12
CL2020000892A1 (es) 2020-10-23
US20200297695A1 (en) 2020-09-24
JOP20200075A1 (ar) 2020-04-30
KR20200066664A (ko) 2020-06-10
TW201922241A (zh) 2019-06-16
CN111432821A (zh) 2020-07-17
JP2020536092A (ja) 2020-12-10
US20260102374A1 (en) 2026-04-16
US12533342B2 (en) 2026-01-27
BR112020006658A2 (pt) 2020-09-24
AU2018345317A1 (en) 2020-05-07
MX2020003670A (es) 2020-08-03
SG11202003009QA (en) 2020-04-29
EP3691652A4 (en) 2021-07-07
US20220288024A1 (en) 2022-09-15
AU2018345317B2 (en) 2024-10-24
PH12020550249A1 (en) 2021-02-15
WO2019070591A1 (en) 2019-04-11
MY200934A (en) 2024-01-24

Similar Documents

Publication Publication Date Title
Willems et al. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics
JP2025060754A (ja) 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
US20260102374A1 (en) Methods of treating bacterial infections
AU2018201772A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
JP6837700B2 (ja) ジピベフリンの使用方法
JP7579239B2 (ja) 鎌状赤血球症を処置するためのｐｄｅ９阻害剤
WO2016131100A1 (en) Methods of treating infectious diseases
CN118695864A (zh) 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
US20180029997A1 (en) Quinazolinone antibiotics
TW202106690A (zh) 皮膚型紅斑狼瘡之治療
US20220257536A1 (en) Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
CN110087655A (zh) 9-氨基甲基米诺环素化合物及其在治疗社区获得性细菌性肺炎(cabp)中的用途
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
CN109715152A (zh) 医治感染的方法
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
TWI705814B (zh) 醫藥組成物及其用途
US20250352663A1 (en) Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
KR101944124B1 (ko) 약학 조성물